ClinicalTrials.gg
RecruitingNCT06869473AVEC-119Updated Mar 14, 2025

Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.

A Phase 2 interventional study of Cetuximab/avelumab in Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer and Metastatic Head and Neck Cancer, sponsored by Gruppo Oncologico del Nord-Ovest. Recruiting at 8 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-14.

Sponsored by Gruppo Oncologico del Nord-Ovest · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 19 under way, 7 of them phase 3. Cetuximab · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
28th of 84
67 · median 46
Started
2025
with 5 others
Phase 2
41 of 86
6 open now
Primary completion
2027-08
later than 8 of 18 live
Registered
80th of 86
by date
Lead sponsor
2 of 86
Gruppo Oncologico del Nord-Ovest

Among the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, this one is the 28th largest by planned enrollment of the 84 interventional ones that give a count, is one of 6 that started in 2025, is one of 41 in phase 2, reaches primary completion later than 8 of the 18 other live ones, and was the 80th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

11 of the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This phase II interventional clinical trial aims to evaluate whether combining cetuximab and avelumab, after three cycles of platinum and taxane-based chemotherapy, can improve treatment outcomes for patients with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) with a PD-L1 combined positive score (CPS) between 1 and 19. Specifically, the study seeks to determine if this approach can increase the 6-month progression-free survival (PFS) rate from 40% to 55%.

The trial will include adult patients with confirmed R/M HNSCC, who have not previously received systemic therapy for their advanced disease. By testing this sequential treatment strategy, researchers hope to improve outcomes for this specific patient population, which has shown poorer responses to existing immunotherapy options compared to those with higher PD-L1 expression levels.

Participants will first undergo an induction phase, consisting of three cycles of chemotherapy with paclitaxel, platinum (cisplatin or carboplatin), and cetuximab. After this initial treatment, they will move to a maintenance phase, where they will receive avelumab and cetuximab every two weeks until disease progression or the occurrence of unacceptable side effects.

The study aims to answer several key questions:

Can this treatment approach improve progression-free survival at 6 months? What impact does it have on overall survival, response rates, and the duration of response? Is this combination therapy safe and well-tolerated? In addition to the treatment itself, participants will be asked to provide blood and tumor tissue samples for translational research, helping scientists better understand how biomarkers influence treatment response. Regular follow-up assessments will also be conducted to monitor disease progression and overall health.

By testing this innovative treatment sequence, researchers hope to bridge the gap between different PD-L1 subgroups, potentially offering a more effective and personalized approach for patients with R/M HNSCC.

Read the detailed description

This clinical study, titled AVEC-119, is a phase II, single-arm trial designed to evaluate the efficacy and safety of an innovative treatment approach for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The study aims to explore whether reversing the conventional immunotherapy sequence-initiating treatment with anti-EGFR-based chemotherapy induction followed by checkpoint inhibition-can significantly improve patient outcomes. The therapy consists of Cetuximab in combination with platinum- and taxane-based chemotherapy during the induction phase, followed by maintenance therapy with Avelumab (a PD-L1 inhibitor) and Cetuximab.

Objective:

The primary goal of this study is to determine whether this unique sequential treatment strategy can enhance six-month progression-free survival (PFS) rates in patients with PD-L1 CPS≥1≤19 R/M HNSCC. By leveraging the potential immune-stimulating effects of anti-EGFR therapy and chemotherapy, followed by immunotherapy maintenance, the study aims to improve overall survival and tumor response rates compared to standard treatment regimens.

Rationale:

Over the past decade, immune checkpoint inhibitors (ICIs) have reshaped the first-line treatment landscape for R/M HNSCC. Findings from the Keynote-048 trial demonstrated that pembrolizumab, administered alone or in combination with chemotherapy, led to prolonged overall survival (OS) compared to the EXTREME regimen (Cetuximab + platinum + 5-FU). However, these improvements were primarily observed in patients with a PD-L1 CPS≥20. In contrast, those with PD-L1 CPS between 1 and 19 did not achieve significant benefits in progression-free survival (PFS) or overall response rate (ORR), highlighting an area of unmet clinical need.

Previous studies have demonstrated that regimens incorporating Cetuximab with platinum- and taxane-based chemotherapy offer comparable efficacy and superior safety profiles compared to platinum + 5-FU regimens. Furthermore, taxanes and anti-EGFR therapies may enhance anti-tumor immune responses, priming the tumor microenvironment for subsequent immunotherapy.

AVEC-119 aims to harness this synergy by first reducing the tumor burden and modulating the immune microenvironment through induction therapy with Cetuximab and chemotherapy, followed by immune checkpoint inhibition with Avelumab in combination with Cetuximab. This innovative treatment approach is designed to improve response rates and extend survival in patients who typically derive limited benefit from standard checkpoint inhibitors.

Study Design:

Study Type: Multicenter, single-arm, phase II trial Participating Sites: 8 specialized oncology centers in Italy Target Population: Patients with R/M HNSCC and PD-L1 CPS between 1 and 19 Planned Enrollment: A total of 67 patients

Treatment Plan:

Induction Phase (TPE - 9 weeks):

  • Paclitaxel: 175 mg/m² IV infusion every 21 days (3 cycles)
  • Cisplatin: 75 mg/m² IV infusion every 21 days (3 cycles) (Carboplatin AUC 5 may be substituted for patients with renal impairment or neuropathy)
  • Cetuximab: Initial dose of 400 mg/m² IV infusion, followed by 250 mg/m² weekly for 3 cycles

Maintenance Phase (AVEC - Until Disease Progression or Toxicity):

  • Avelumab: 800 mg IV every 2 weeks
  • Cetuximab: 500 mg/m² IV every 2 weeks Translational Research and Biomarker Analysis AVEC-119 integrates a comprehensive translational research component aimed at unraveling the molecular mechanisms underlying treatment response and resistance.

The study will:

  • Conduct pre-treatment gene expression (GE) analysis in tumor samples to explore correlations between hypoxia, immune activity, and response to therapy.
  • Utilize single-cell sequencing to track immune cell population changes in blood samples collected at four critical time points: pre-TPE, post-TPE, during maintenance (6 months), and at disease progression.
  • Investigate whether the hypoxic and immune landscape of tumors shifts following EGFR inhibition, potentially enhancing response to subsequent PD-L1 blockade.

Ethical and Regulatory Aspects

  • The study adheres to Good Clinical Practice (GCP) standards and has obtained approval from the relevant ethics committees.
  • All participants provide informed consent prior to enrollment.
  • Patient safety is continuously monitored, with predefined stopping criteria in place should unacceptable toxicity levels arise.

Conclusion AVEC-119 represents a paradigm shift in the treatment of R/M HNSCC, particularly for patients with PD-L1 CPS between 1 and 19, a group that has historically exhibited suboptimal responses to checkpoint inhibitors. By reversing the conventional immunotherapy sequence-priming the immune system with a chemotherapy/EGFR-targeted induction before introducing checkpoint blockade-this study aims to achieve higher response rates, prolong progression-free survival, and shed new light on tumor-immune dynamics. If successful, this approach may redefine first-line treatment strategies for a challenging subset of head and neck cancer patients, offering new hope and improved clinical outcomes.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Recurrent Head and Neck Cancer
  • Metastatic Head and Neck Cancer

Keywords

  • Head and Neck Neoplasms
  • Squamous Cell Carcinoma
  • Cetuximab
  • Avelumab
  • Anti-EGFR Therapy
  • Platinum-Based Chemotherapy
  • Taxane-Based Chemotherapy
  • PD-L1 Combined Positive Score (CPS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects able to sign the and ≥18 y-old.
  2. or cytologically confirmed diagnosis of HNSCC.
  3. Confirmed R/M HNSCC (i.e. oral cavity, oropharynx, larynx, hypopharynx) not suitable for curative loco-regional therapy.
  4. CPS≥1≤19 (assessment allowed either on primary and/or recurrent/ site of disease).
  5. according to Criteria 1.1.6. Subjects should not have had prior systemic therapy administered in the R/M HNSCC setting.

7.Systemic therapy that was completed more than 6 months prior to signing consent, if given as a part of multimodal curative treatment for locally advanced disease, is allowed.

8. Performance Status (PS) 0-1. 9.Adequate bone marrow function: neutrophils ≥ 1.5 x 109/L, ≥ 100 x 109/L, ≥ 9 g/dL.

10.Adequate liver function: total level \< 1.5 X (ULN) (except for known medical reason not interfering with liver function, such as Gilbert syndrome), AP, GGT \<3 x ULN and and ALT levels ≤ 2.5 × ULN.

11.Adequate renal function: calculated or analyzed ≥ 30 mL/min.

12.Archival or fresh tissue of primary disease (i.e. T and/or N and/or M) OR recurrent/metastatic disease available at baseline (before starting TPE) (available as Formalin-Fixed Paraffin-Embedded - FFPE - or as unstained 10-20 slices).

13.Participants have to provide peripheral blood samples (at least 8-10 mL stored in EDTA) according the timing described in the translational part of the current protocol.

14.Palliative radiotherapy and/or surgery within 4 weeks before the study entry are allowed.

15.Symptomatic peripheral neuropathy NCI-CTC v5.0 grade ≥ 2 and / or ototoxicity grade ≥ 2, (except for cases in which ototoxicity is due to trauma or tumor-related mechanical impairment) or creatinine clearance \< 60 mL/min are acceptable and they must be approached with carboplatin (instead of cisplatin) since the trial start.

Exclusion criteria

Exclusion criteria:

  1. Nasopharyngeal, salivary gland, nasal sinus, and non-melanoma skin cancers are not allowed.
  2. lower than 3 months according to the judgement of trial investigator is not allowed.
  3. Previous chemotherapy, or biological therapy (i.e. Cetuximab), or immunotherapy administered for R/M setting of HNSCC is not allowed.
  4. Diagnosis of immunodeficiency or subjects receiving systemic therapy (> 10 mg/day of prednisone or equivalent) or any other form of therapy within 30 days prior to start of study treatment which cannot be interrupted.
  5. Known allergic/ reaction to products or any component in their formulations.
  6. Active disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
  7. Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with type I diabetes, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
  8. Any diagnosed and/or treated additional within 5 years before the study entry with the exception of: curatively treated basal cell carcinoma of the skin, curatively treated squamous cell carcinoma of the skin, curatively treated prostate cancer, curatively resected in situ cervical cancer, and curatively resected in situ breast cancer.
  9. Subjects with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subjects' participation for the full duration of the trial, or is not in the best interest of the subject to participate, according to the opinion of the treating investigator.
  10. Significant neurologic or known psychiatric or substance abuse disorders that would interfere with cooperation and the requirements of the trial.
  11. (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (≤6 months prior to enrollment), myocardial infarction (≤6 months prior to enrollment), unstable angina, congestive heart failure (≥ Classification Class II), or serious cardiac arrhythmia requiring medication.
  12. Prior organ transplantation including allogenic stem-cell transplantation.
  13. Active uncontrolled infection requiring systemic therapy (i.e. I.V. antibiotics).
  14. Known history of testing positive for or known acquired immunodeficiency syndrome.
  15. virus (HBV) or virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening tests positive).
  16. within 30 days of planned start of study treatment (inactivated vaccines are allowed).
  17. Pregnancy (absence of pregnancy must be confirmed by negative serum or urine pregnancy test - ß-HCG - for women of ) and/or breast-feeding are not allowed. Subjects of childbearing potential willing to use effective method [Pearl Index \< 1; e.g. oral contraceptive (pill), hormone spiral, hormone implant, transdermal patch, a combination of two barrier methods (condom and diaphragm), sterilization, sexual abstinence] for the entire study duration and 30 days post-dosing.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (estimated)

Study arms

  • Experimental
    single-arm

    in-label induction therapy with three cycles of TPE (Paclitaxel, platinum-based compound, Cetuximab), followed, only in patients who are (partially or completely) responders and stable, by a maintenance therapy with the combination of AVEC (Avelumab, an anti-PD-L1 drug, plus Cetuximab, an anti-EGFR drug) extended until disease progression, unacceptable toxicity, or patient withdrawal.

    Drug: Cetuximab/avelumab

Interventions

  • DrugCetuximab/avelumab

    Drug pages: CetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AvelumabStudies of AvelumabAvelumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Study Maintenance therapy: AVEC (each cycle every 2 weeks) Cetuximab will be administered at 500 mg/m2 dose (as a 2-hour intravenous infusion) every 2 weeks until disease progression or unacceptable side effects. Cetuximab will be administered by IV infusion over 120 minutes. The initial dose should be given slowly and speed of infusion must not exceed 5 mg/min. Avelumab will be administered at 800 mg flat dose (as a 1-hour intravenous fusion) every 2 weeks until disease progression or unacceptable side effects.

06

What researchers measure

Primary outcomes

  1. 6-months (6m)-Progression Free Survival

    The increase of the 6-months (6m)-Progression Free Survival intended as the time from baseline until first evidence of disease progression or death, from 40% to 55% in PD-L1 CPS≥1≤19 R/M HNSCC patients.

    Time frame: 6-months from baseline

Secondary outcomes

  1. overall survival (OS)

    Overall Survival (OS) of TPE followed by avelumab and cetuximab in PD-L1 CPS≥1≤19 R/M HNSCC patients.

    Time frame: From date of enrollment until the date of first documented until the date of death from any cause, assessed up to 12 months from last subject in

  2. overall response rate (ORR)

    overall response rate (ORR) of cetuximab plus platinum and taxane-based chemotherapy followed by avelumab and cetuximab maintenance.

    Time frame: Up to 12 months

  3. safety of cetuximab plus platinum and taxane-based chemotherapy

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: up to 12 months

  4. duration of response (DOR)

    duration of response (DOR) of cetuximab plus platinum and taxane-based chemotherapy followed by avelumab and cetuximab maintenance.

    Time frame: Up to 12 months

07

Study locations

3 of 8 sites recruiting
  • Irccs Humanitas Research Hospital
    Rozzano, Milano 20089, Italy
    Not yet recruiting
    • Paolo Bossi, Principal investigator · Contactpaolo.bossi@hunimed.eu · +390282243660
    • Paolo Bossi, Principal Investigator · Principal investigator
  • Ospedale Oncologico "A. Businco" ARNAS BROTSU
    Cagliari, 09121, Italy
    Not yet recruiting
    • Maria Chiara Cau, Principal investigator · Contactmariac.cau@aob.it · +3907052962070
    • Maria Chiara Cau, Principal Investigator · Principal investigator
  • Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico-S. Marco
    Catania, 95123, Italy
    Not yet recruiting
    • Hector Jose Soto Parra, Principal investigator · Contacthsotoparra.ctu@gmail.com · +390953782496
    • Hector Jose Soto Parra, Principal Investigator · Principal investigator
  • Azienda Ospedaliero-Universitaria Careggi
    Firenze, 50134, Italy
    Recruiting
    • Lorenzo Livi, Principal investigator · Contactlorenzo.livi@unifi.it · +390557947019
    • Lorenzo Livi, Principal Investigator · Principal investigator
  • Fondazione IRCCS Istituto Nazionale dei Tumori (INT) di Milano
    Milano, 20133, Italy
    Recruiting
  • Irccs Fondazione G. Pascale
    Napoli, 80131, Italy
    Recruiting
    • Francesco Perri, Principal investigator · Contactf.perri@istitutotumori.na.it · +3908117770412
    • Francesco Perri, Principal Investigator · Principal investigator
  • AOU Luigi Vanvitelli
    Napoli, 80138, Italy
    Not yet recruiting
    • Morena Fasano, Principal investigator · Contactmorena.fasano@unicampania.it · +393388902011
    • Morena Fasano, Principal Investigator · Principal investigator
  • Azienda Ospedaliero-Universitaria Sant'Andrea
    Roma, 00189, Italy
    Not yet recruiting
    • Andrea Botticelli, Principal investigator · Contactandrea.botticelli@uniroma1.it · +390649977800
    • Andrea Botticelli, Principal Investigator · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — due to technical issues

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Aug 2027, 30 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 30 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Mar 11, 2025
StartActual
Feb 20, 2025
Primary completionEst.
Aug 20, 2027
CompletionEst.
Feb 20, 2028
Last update
Mar 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06869473
Lead sponsor
Gruppo Oncologico del Nord-Ovest
Collaborators
Merck Serono S.P.A., Italy, Clinical Research Technology S.r.l.
Responsible party
Sponsor
First posted
Mar 11, 2025
Start date
Feb 20, 2025
Primary completion
Aug 20, 2027 (estimated)
Completion
Feb 20, 2028 (estimated)
Last update
Mar 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Avelumab

Start the discussion